Pfizer (NYSE:PFE) - Page 2

Intel Overtakes Pfizer as Most Shorted Dow Stock

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components. Short sellers are betting on these companies to fail, or ...
Read Full Story »

Big Pharma Sees Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

The 5 Most Shorted Dow Stocks

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components. Short sellers are betting on these companies to fail, or ...
Read Full Story »

Merrill Lynch Has 5 Stocks to Buy That Could Beat Q2 Earnings Estimates

The ongoing trade and tariff issues most likely will have the greatest impact when companies report second-quarter earnings. Needless to say, investors are wary of the constant back and forth ...
Read Full Story »

Many Top Pharma & Biotechs Rise as Drug Price Disclosure Thrown Out

While the public wants more pharmaceuticals and biotech advancements to treat the endless number of ailments or to extend their lives, there is a simultaneous push to make drugs more ...
Read Full Story »

Will Sangamo and Pfizer’s Hemophilia Gene Therapy Keep Building Momentum?

Sangamo Therapeutics, Inc. (NASDAQ: SGMO) made a handy gain to start out the week after the firm, in conjunction with Pfizer Inc. (NYSE: PFE), announced updated results from a mid-stage ...
Read Full Story »

How Pfizer Is Looking to Expand Its Eczema Treatment

Pfizer Inc. (NYSE: PFE) has announced topline results from its most recent late-stage study in children aged 3 months to less than 24 months with mild to moderate atopic dermatitis ...
Read Full Story »

Pfizer’s Duchenne Muscular Dystrophy Pain Could Make Sarepta the DMD King

Pfizer Inc. (NYSE: PFE) has released initial clinical data from its Phase 1b gene therapy study for Duchenne muscular dystrophy (DMD). While these results did not necessarily live up to ...
Read Full Story »

Short Sellers Seek Direction on Big Pharma

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

The 6 Most Shorted Dow Stocks

It takes a certain kind of courage to short sell blue chips, such as the Dow Jones industrial average components. Short sellers are betting on these companies to fail, or ...
Read Full Story »

5 Dow Stocks Not Allowing the DJIA a Proper Rally

The markets have been on a wild ride in this year. The seasonal theme of “Sell in May and go away” passed and seemingly has turned into “Hold your nose ...
Read Full Story »

5 Dividend Leaders To Buy From Merrill Lynch’s Large Cap Defensive Portfolio

With summer starting on Friday, we could be in for a hot three months in more ways than one. On-going trade battles, the potential for escalation of tensions in the ...
Read Full Story »

How Much Is Pfizer Overpaying For Array Bio?

Array BioPharma Inc. (NASDAQ: ARRY) shares shot up on Monday after the firm announced that it would be acquired by Pfizer Inc. (NYSE: PFE) in an all cash transaction. The ...
Read Full Story »

7 Stocks Not Enjoying the Bull Market and Holding Down the Dow in 2019

It's been a wild ride in 2019. The seasonal theme of "sell in May and go away" passed and seemingly has turned into "Hold your nose and buy in June." ...
Read Full Story »

Big Pharma Sees a Rising Tide in Short Interest

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »